7 July 2014
JenaValve Technology, Inc., a privately-held, venture-backed developer, manufacturer and marketer of transcatheter aortic valve implantation (TAVI) systems for the treatment of aortic valve disease, today announced that medical device industry veteran David J. Drachman has been named the Company’s new chief executive officer, effective immediately.
27 June 2014InDex Pharmaceuticals announces results from COLLECT, a clinical trial of Kappaproct® in the treatment of moderate to severe Ulcerative Colitis
InDex Pharmaceuticals today reported top-line results from the double blind, placebo-controlled clinical study COLLECT. The aim of the COLLECT study was to investigate the therapeutic potential of the Toll-like receptor 9 agonist Kappaproct as an add-on therapy for patients with moderate to severe, chronic active Ulcerative Colitis.
4 June 2014
JenaValve Technology, Inc., a privately-held, venture-backed developer, manufacturer and marketer of transcatheter aortic valve implantation (TAVI) systems for the treatment of aortic valve disease, announced today that it has successfully completed the first implantation of its second-generation transapical JenaValve TAVI system in Sweden.
27 May 2014
Sonendo®, Inc., the developer of a revolutionary technology for the endodontic marketplace, announced today that it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for the second generation of its Multisonic Ultracleaning System for root canal therapy. The system is designed to be a minimally-invasive, disruptive technology that utilizes multiple wavelengths of sound to clean the entire root canal system simultaneously.
7 May 2014St. Jude Medical Announces TOCCASTAR Clinical Trial Meets Primary Safety and Efficacy Endpoints at Heart Rhythm 2014
St. Jude Medical, Inc. (NYSE:STJ), a global medical device company, today announced results of the TOCCASTAR clinical trial at Heart Rhythm 2014, the Heart Rhythm Society’s 35th Annual Scientific Sessions in San Francisco. Results from the first prospective, randomized study of contact-force ablation technology for the treatment of paroxysmal atrial fibrillation (AF) met primary endpoints and supplement the growing body of evidence that supports the safety and effectiveness of contact-force ablation technology.